{"prompt": "['SPIMM-301 Version 4.0', '15 June 2018', '11.2.5.5.', 'Adjustments for Multiplicity', '75', '11.2.5.6.', 'Handling of Missing Data', '75', '11.2.6.', 'Pharmacokinetics (PK)', '76', '11.2.7.', 'Safety Analyses', '76', '11.2.7.1.', 'Adverse Events (AEs)/Adverse Device Effects (ADEs)', '76', '11.2.7.2.', 'Deaths and Other Serious Adverse Events (SAEs)/Serious Adverse Device', 'Effects (SADEs)', '76', '11.2.7.3.', 'Clinical Laboratory Evaluations', '77', '11.2.7.4.', 'Vital Signs', '77', '11.2.7.5.', 'Electrocardiogram', '77', '11.2.7.6.', 'Other Safety Parameters', '77', '12.', 'INFORMED CONSENT, ETHICAL REVIEW, AND REGULATORY', 'CONSIDERATIONS', '78', '12.1.', 'Informed Consent', '78', '12.2.', 'Ethical Review', '78', '12.3.', 'Regulatory Considerations', '78', '12.3.1.', 'Protocol Approval', '79', '12.3.2.', 'Final Report Approval', '79', '12.3.3.', 'Trial Monitoring', '79', '12.3.4.', 'Retention of Records', '79', '12.3.5.', 'Disclosure of Information', '79', '13.', 'REFERENCES', '81', 'APPENDIX 1. PART 1 SCHEDULE OF ASSESSMENTS', '82', 'APPENDIX 2. PART 2 SCHEDULE OF ASSESSMENTS', '84', 'APPENDIX 3. TRIAL DESIGN SCHEMATIC', '85', 'APPENDIX 4. LIST OF CLINICAL LABORATORY TESTS TO BE PERFORMED', '86', 'APPENDIX 5. COLUMBIA-SUICIDE SEVERITY RATING SCALE (C-SSRS)', '\"BASELINE/SCREENING\\'', '87', 'APPENDIX 6. COLUMBIA-SUICIDE SEVERITY RATING SCALE (C-SSRS)', '\"SINCE LAST VISIT\"', '91', 'APPENDIX 7. SAMPLE SAFETY TELEPHONE CALL SCRIPT', '95', 'APPENDIX 8. PRIMARY MITOCHONDRIAL MYOPATHY SYMPTOM', 'ASSESSMENT (PMMSA)', '96', 'APPENDIX 9. NEURO-QOL FATIGUE', '99', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '18']['SPIMM-301 Version 4.0', '15 June 2018', 'APPENDIX 10. EQ-5D-5L', '102', 'APPENDIX 11. PATIENT GLOBAL IMPRESSION (PGI) SCALES', '106', 'APPENDIX 12. CLINICIAN GLOBAL IMPRESSION (CGI) SCALES', '114', 'APPENDIX 13. 6-MINUTE WALK TEST (6MWT)', '117', 'APPENDIX 14. TABLE FOR GRADING THE SEVERITY OF INJECTION SITE', 'REACTIONS', '118', 'APPENDIX 15. COUNTRY-SPECIFIC APPENDIX--GERMANY.', '119', 'LIST OF TABLES', 'Table 1:', 'Summary of Change from Baseline on Days 5 and 7 in Distance Walked', '(meters) on 6MWT (Trial SPIMM-201)', '28', 'Table 2:', 'Summary of Change from Baseline to Day 28 in Distance Walked (meters)', 'on 6MWT (Trial SPIMM-202)', '29', 'Table 3:', 'Summary of Change from Baseline by Week in PMMSA Fatigue Scores', '(Trial SPIMM-202)', '30', 'Table 4:', 'Summary of Systemic TEAEs Reported in Greater Frequency ( 2%', 'difference) in Elamipretide-treated Subjects Compared to Placebo-Treated', 'Subjects', '32', 'Table 5:', 'Mean Steady-State PK Parameters* on Day 5 (Males and Females', 'Combined) Following Repeat Administration of Elamipretide (MTP-131) at', '0.01, 0.1 and 0.25 mg/kg/hr as a 2-hour IV infusion, Once Daily, for 5 Days', '(Trial SPIMM-201)', '35', 'Table 6:', 'Estimated Bioavailability of SC Administration (40 mg as a 1 mL injection)', 'Versus Two Hour IV Infusion Following Repeat Administration of', 'Elamipretide (MTP-131) (Trial SPIMM-201)', '36', 'Table 7:', 'Key Summary Steady-State PK Parameters Days 182 (Rat) and 273 (Dog) at', 'the NOAEL/MFD with Safety Margins Versus. Human Exposure (SPISC-', '101, 40 mg/day) (Study SPI-CIT-15-03 and Study SPI-CIT-15-02)', '37', 'LIST OF FIGURES', 'Figure 1: Oxidative Phosphorylation', '24', 'Figure 2: Creation of Reactive Oxygen Species (ROS)', '25', 'Figure 3: SPIMM-202 Summary of Treatment Effect (Analysis Population -', 'Intention-to-Treat [ITT]', '31', 'Figure 4:', 'Elamipretide Delivery System (expanded view of major components)', '59', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '19']\n\n###\n\n", "completion": "END"}